A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Apararenone (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2015 New trial record